Pharvaris: Strong Buy Rating Backed by Clinical Progress and Financial Stability

Analyst Joseph Schwartz from Leerink Partners reiterated a Buy rating on Pharvaris (PHVS – Research Report) and keeping the price target at $28.00.

Joseph Schwartz has given his Buy rating due to a combination of factors including Pharvaris’s progress in their clinical trials and the potential of their lead candidate, deucrictibant, to address unmet needs in hereditary angioedema (HAE) treatment. The company is advancing two key studies, RAPIDe-3 and CHAPTER-3, with expected data readouts in 2026, which are crucial for evaluating the efficacy of deucrictibant in both on-demand and prophylactic settings.
Additionally, Pharvaris has received favorable regulatory feedback, including thorough QT waivers from the FDA, which mitigate concerns about cardiovascular risks associated with their drug. The company’s strong financial position, with sufficient cash reserves to support operations into the third quarter of 2026, and upcoming R&D events further bolster confidence in its future prospects. These elements collectively support Schwartz’s positive outlook and reaffirmation of the stock’s outperform rating with a price target of $28.

In another report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $43.00 price target.

PHVS’s price has also changed moderately for the past six months – from $20.040 to $16.110, which is a -19.61% drop .